title: Adherence to treatment guidelines for cancer-associated thrombosis: a French hospital-based cohort study.
abstract: French 2008 treatment guidelines recommend low-molecular-weight heparins (LMWH) for the treatment of cancer-associated thrombosis (CAT) with treatment duration of at least 3 months and up to 6 months and beyond if cancer remains active. Our aim was to assess adherence to guidelines in hospital clinical practice.
  
  
  
  The French hospital database (PMSI) was used to identify patients with CAT admitted to three hospitals of the Paris region to be included in a retrospective cohort study. Adherence to guidelines was assessed in patients included from different treatment periods following the venous thromboembolism (VTE) episode i.e. first 10 days (T1), day 10 to 3 months (T2), months 3 to 6 (T3) and beyond 6 months (T4) when applicable.
  
  
  
  A total of 240 patients with CAT were included from January 2012 to December 2012 of whom 204 were analyzable. Treatment was adherent to guidelines in 55, 31 and 34 % of patients in T1, T2 and T3 treatment periods, respectively, while overall treatment adherence was found in 52 % of patients. Adherence rates were the highest among patients with pulmonary embolism (PE, 60.5 %), catheter-related thrombosis (62.5 %), class III/IV extended cancer (58.0 %) and metastatic malignancy (60.3 %) while only 40 % with deep vein thrombosis (DVT) received a treatment consistent with guidelines.
  
  
  
  Adherence to guidelines appears insufficient since only half of patients received an appropriate treatment. Adherence dropped significantly across treatment periods T2 and T3. VTE diagnosis and cancer characteristics influenced the anticoagulant prescription. Management of patients with CAT requires further education and information of health care professionals.
authors.affiliation: Hôpital Louis-Mourier, Service de Médecine Interne (APHP), Paris 7 University, 92700, Colombes, France. Isabelle.mahe@aphp.fr.|EA 7334 Recherche Clinique, Coordonnée Ville-Hôpital, Méthodologies et Société (REMES), Paris Diderot, Sorbonne Paris Cite, Paris, France. Isabelle.mahe@aphp.fr.
authors.forename: I
authors.initials: I
authors.lastname: Mahé
authors.affiliation: Hôpital Louis-Mourier, Service de Médecine Interne (APHP), Paris 7 University, 92700, Colombes, France.
authors.forename: H
authors.initials: H
authors.lastname: Puget
authors.affiliation: Hôpital Bichat, Medical Information Systems Program (PMSI), APHP, University Paris 7, Paris, France.
authors.forename: J C
authors.initials: JC
authors.lastname: Buzzi
authors.affiliation: Hôpital Louis-Mourier, Service de Médecine Interne (APHP), Paris 7 University, 92700, Colombes, France.
authors.forename: M
authors.initials: M
authors.lastname: Lamuraglia
authors.affiliation: Hôpital Louis-Mourier, Service de Médecine Interne (APHP), Paris 7 University, 92700, Colombes, France.
authors.forename: J
authors.initials: J
authors.lastname: Chidiac
authors.affiliation: Hôpital Bichat, Medical Information Systems Program (PMSI), APHP, University Paris 7, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Strukov
authors.affiliation: Hôpital Louis-Mourier, Service de Médecine Interne (APHP), Paris 7 University, 92700, Colombes, France.
authors.forename: Hélène
authors.initials: H
authors.lastname: Helfer
authors.affiliation: Hôpital Bichat, Medical Information Systems Program (PMSI), APHP, University Paris 7, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Perozziello
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D019983:Guideline Adherence / Q000706:statistics & numerical data*; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use*; D006760:Hospitalization; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000150:complications*; D012189:Retrospective Studies; D054556:Venous Thromboembolism / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight
keywords: Cancer; Low-molecular-weight heparin; Practice; Standard; Venous thromboembolism